MOPP/ABVD Chemotherapy for Advanced Hodgkin's Disease
Authors: JOHN H. GLICK
Journal: Annals of Internal Medicine (1986)

Editorials1 June 1986MOPP/ABVD Chemotherapy for Advanced Hodgkin's DiseaseJOHN H. GLICK, M.D., ANASTASIOS TSIATIS, Ph.D.JOHN H. GLICK, M.D.Search for more papers by this author, ANASTASIOS TSIATIS, Ph.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-104-6-876 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn the past 2 decades, the prognosis of patients with advanced Hodgkin's disease has improved dramatically because of the development of curative combination chemotherapy. The MOPP regimen (mechlorethamine, vincristine, procarbazine, prednisone) represents the standard against which all alternative chemotherapy or combined modality programs must be judged. The landmark studies of DeVita and colleagues (1) have shown that more than 50% of patients with advanced Hodgkin's disease are cured with chemotherapy alone. Subsequent studies, both by single institutions and cooperative groups, have confirmed the effectiveness of MOPP chemotherapy (2, 3). The importance of administering full doses of MOPP in a timely...References1. DEVITASIMONHUBBARD VRS. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980;92:587-95. LinkGoogle Scholar2. GLICK J. Chemotherapy of Hodgkin's and non-Hodgkin's lymphoma. In: BENNETT JM, ed. Lymphomas I. The Hague: Martinus Nijhoff Publishers BV; 1981; 343-446. CrossrefGoogle Scholar3. CANELLOSCOMESKARIN GSA. Chemotherapy in the treatment of Hodgkin's disease. Semin Oncol. 1983;20:1-24. Google Scholar4. CARDEMACKINTOSHROSENBERG PFS. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983;1:146-53. CrossrefMedlineGoogle Scholar5. SANTOROBONFANTEBONADONNA AVG. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982;96:139-43. LinkGoogle Scholar6. CANELLOS G. Bone marrow transplantation as salvage therapy in ad vanced Hodgkin's disease: allogeneic or autologous [Editorial]. J Clin Oncol. 1985;3:1451-4. CrossrefMedlineGoogle Scholar7. BONADONNAVALAGUSSASANTORO GPA. Alternating non-cross-resistant combination chemotherapy or MOPP in state IV Hodgkin's disease: a report of 8-year results. Ann Intern Med. 1986;104:739-46. LinkGoogle Scholar8. DEVITAHUBBARD VS. The curative potential of chemotherapy in the treatment of Hodgkin's disease and non-Hodgkin's lymphomas. In: Rosenberg RS, Kaplan HS, eds. Malignant Lymphomas, Etiology, Immunology, Pathology, Treatment. New York: Academic Press; 1982:379-418. Google Scholar9. ROSENBERGKAPLAN SH. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys. 1985;11:5-22. CrossrefMedlineGoogle Scholar10. BAKEMEIERANDERSONCOSTELLO RJW. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with MOPP regimen: results of an Eastern Cooperative Oncology Group study. Ann Intern Med. 1984;101:447-56. LinkGoogle Scholar11. TSIATIS A. A nonidentifiability aspect of the problem of competing risks. Proc Natl Acad Sei USA. 1975;72:20-2. CrossrefMedlineGoogle Scholar12. GOLDIECOLDMAN JA. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727-33. MedlineGoogle Scholar13. KLIMOCONNORS PJ. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol. 1985;3:1174-82. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySecond malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trialsChemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer riskClinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphomaComparison of Different Treatment strategies for Diffuse Large-cell LymphomasTherapiekonzepte 1 June 1986Volume 104, Issue 6Page: 876-878KeywordsChemotherapyCombination chemotherapyHodgkin lymphomaMechlorethamineProcarbazine Issue Published: 1 June 1986 PDF DownloadLoading ...